Akebia Therapeutics, Inc. (AKBA) vs Century Therapeutics, Inc. (IPSC)
A side-by-side comparison of Akebia Therapeutics, Inc. and Century Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKBA
Akebia Therapeutics, Inc.
$0.88HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
IPSC
Century Therapeutics, Inc.
$1.32HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AKBA vs IPSC
growth of $100 · dividends reinvested · last 5yAKBA -75.2% (-24.3%/yr)IPSC -93.5% (-42.1%/yr)AKBA compounded faster over this window
AKBA IPSC
AKBA vs IPSC: by the numbers
- •IPSC is the larger company ($239M vs $236M market cap).
- •Both run net losses; IPSC's is the smaller (-8.78% vs -13.54% net margin).
Metrics side by side
Valuation
| Metric | AKBA | IPSC |
|---|---|---|
| P/S ratio | 1.08 | N/A |
| P/B ratio | 9.42 | 1.03 |
| FCF yield | 17.05% | N/A |
Profitability
| Metric | AKBA | IPSC |
|---|---|---|
| Gross margin | 79.48% | 88.00% |
| Operating margin | 9.95% | -13.78% |
| Net margin | -13.54% | -8.78% |
| ROE | -118.58% | -47.25% |
| ROIC | -7.08% | -43.69% |
Growth (annualized)
| Metric | AKBA | IPSC |
|---|---|---|
| Revenue CAGR (5Y) | -0.26% | N/A |
| Total return CAGR (5Y) | -20.07% | -42.05% |
Frequently asked
- How have AKBA and IPSC total returns compared?
- Over the past 5 years, AKBA delivered -20.07% and IPSC delivered -42.05% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Akebia Therapeutics ROECentury Therapeutics ROEAkebia Therapeutics operating marginCentury Therapeutics operating marginAkebia Therapeutics revenue growthCentury Therapeutics revenue growthAkebia Therapeutics free cash flowCentury Therapeutics free cash flow
Akebia Therapeutics & Century Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.